Hypercholesterolemia represents a major cardiovascular risk factor because of its ability to
promote and sustain proatherogenic inflammation of vascular wall. 1 A reduction of number …

Circulating endothelial progenitor cells (circEPCs) of bone marrow (BM) origin contribute to
postnatal neovascularization and represent a potential therapeutic target for ischemic …

Statins have been shown to favorably affect the prognosis of patients with risk factors to
atherosclerosis—both as a primary and a secondary prevention. The beneficial effects …

3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely
used to decrease cholesterol synthesis and are well established to reduce vascular …

Endothelial progenitor cells (EPCs) are vital for the maintenance and repair of the
endothelium. Decreased EPC number and function have been associated with increased …

Objective: Endothelial function is an independent predictor of prognosis in heart failure (HF)
subjects. Statins, beyond their lipid lowering role, exert beneficial effect in patients with …

BACKGROUND: Statins are known to have pleiotropic effects. We examined the effect and
mechanism of simvastatin therapy on EPC differentiation and pro-angiogenic cytokines in …

Statins enhance incorporation of bone marrow-derived cells into experimental neointimal
lesions. However, the contribution of progenitor cells to progression of spontaneous …

Circulating bone marrow-derived vascular progenitor cells contribute to angiogenesis,
atherosclerosis, and the response to vascular injury. These vascular progenitor cells consist …

Circulating endothelial progenitor cells (EPC) contribute to endothelial replenishment.
Telmisartan is an angiotensin‐receptor blocker with PPARγ‐agonistic properties. PPARγ …